GSK stock costs EUR 20.89 with USD 93.2 billion market value

Published on 10/12/2026 at 14:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock costs EUR 20.89 on October 12, 2026, between bid EUR 20.87 and ask EUR 20.90. Market value is USD 93.2 billion.

Key points in brief

GSK stock stood at EUR 20.89 at Lang & Schwarz on October 12, 2026 at 2:15 p.m. CEST.
The market capitalization was USD 93.2 billion, with a P/E ratio of 14.82 and a dividend yield of 4.00 percent.
The LSE close was GBp 1,750.00 on October 9, 2026, while JPMorgan maintained an Underweight rating and a GBp 1,700.00 target.
GSK's next reported earnings date is October 28, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK stock stood at EUR 20.89 at Lang & Schwarz on October 12, 2026 at 2:15 p.m. CEST, with a bid of EUR 20.87 and an ask of EUR 20.90. The quote gives investors a live euro reference while the latest available home-market close was GBp 1,750.00 on the London Stock Exchange on October 9, 2026.

Price sits beside a large valuation

The finance snapshot puts GSK's market capitalization at USD 93.2 billion as of October 9, 2026. Its P/E ratio was 14.82 and its trailing dividend yield was 4.00 percent on the same date, giving the valuation paragraph a clear income and earnings dimension.

GSK's primary listing is in London under ticker GSK.L, according to Global Banking and Finance Review. The source identifies the ordinary share as GBp-denominated and records the October 9 close at GBp 1,750.00.

Comparison with peers

GSK: P/E 14.82, dividend yield 4.00 percent, market capitalization USD 93.2 billion

AstraZeneca (USD): plus 0.26 percent, P/E 23.92, market capitalization USD 246.9 billion

Novartis (USD): plus 0.45 percent, P/E 21.96, market capitalization USD 273.2 billion

The comparison places GSK below the two larger pharmaceutical names on the reported earnings multiple. GSK's 4.00 percent dividend yield also exceeds the 2.00 percent yield shown for AstraZeneca and the 3.00 percent yield shown for Novartis, although the figures use the USD market quotations supplied for the peer comparison.

Analyst target stays below the quote

JPMorgan maintained an Underweight rating and a GBp 1,700.00 price target for GSK in an analyst note dated October 7, 2026, as reported by wallstreetONLINE. The target was unchanged, and the note cited expectations for a solid third quarter while flagging possible pressure from Blenrep and Exdensur.

Results date approaches

GSK's next earnings date is October 28, 2026, according to Stock Analysis. That calendar point gives the current valuation figures a defined near-term reference, while the market report remains centered on the euro quote rather than a forecast.

GSK stock and the London market

The combination of EUR 20.89 at Lang & Schwarz, USD 93.2 billion in market capitalization and a 14.82 P/E ratio frames GSK as a large listed healthcare company with a visible income component. JPMorgan's GBp 1,700.00 target and the October 28, 2026 results date provide the two clearest reference points for the next market assessment.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.